"Mount Sinai And RenalytixAI Launch Groundbreaking Artificial Intelligence Solution For Improved Kidney Disease Management and Patient Care"
Mount Sinai Health System and RenalytixAI, Plc today have entered into an exclusive multi-year license and collaboration to commercialize artificial intelligence solutions to improve kidney disease detection, management and treatment for patients with diabetes and other at-risk, large-scale patient populations. “Our ability to apply the power of artificial intelligence against such a deep repository of clinical data in combination with prognostic biomarkers has the potential to change the game for all of our patients with diabetes and other populations at risk for kidney disease,” said Barbara Murphy, MD, dean for clinical integration and population health management and chair for the department of internal medicine at the Icahn School of Medicine at Mount Sinai, and chief executive officer of RenalytixAI. The accomplished innovators and rich data resources of Mount Sinai combined with the expertise and vision of our colleagues at RenalytixAI are evolving the development of cutting-edge renal prognostics for the benefit of patients and healthcare globally,” said Erik Lium, PhD, senior vice president at Mount Sinai Innovation Partners.
- Barbara Murphy, MD, Dean, Clinical Integration and Population Health, Chair, Department of Medicine, Icahn School of Medicine at Mount Sinai
- Erik Lium, PhD, Senior Vice President, Mount Sinai Innovation Partners
Additional coverage:
Star Tribune
Pittsburgh Post-Gazette
The Buffalo News
Street Insider
Channel 8 Eyewitness News
Crain’s New York
Crain’s Health Pulse (Subscription required)
DOTMed
Healthcare Analytics News
Health Data Management
Healthcare Informatics
Fierce Biotech
The Post & Mail